Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3476757 | 0.91 | NAMPT (0.52) | NAMPTALDH1A1MAPTKMT2A | |
| SCHEMBL3477794 | 0.90 | NAMPT (0.57) | NAMPTALDH1A1KMT2A | |
| SCHEMBL3607172 | 0.85 | NAMPT (0.48) | NAMPTALDH1A1MAPTKMT2A | |
| SCHEMBL3476271 | 0.85 | NAMPT (0.57) | NAMPTALDH1A1MAPT | |
| SCHEMBL3478269 | 0.85 | NAMPT (0.42) | NAMPTMAPTKDM4E | |
| SCHEMBL3476812 | 0.85 | NPC1 (0.50) | NAMPTALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL3476335 | 0.85 | NAMPT (0.45) | NAMPTALDH1A1MAPTKMT2A | |
| SCHEMBL3477440 | 0.85 | LMNA (0.43) | ALDH1A1MAPTKMT2A | |
| SCHEMBL3476752 | 0.83 | LMNA (0.43) | NAMPTALDH1A1MAPTKDM4EKMT2A | |
| SCHEMBL3477801 | 0.82 | ALDH1A1 (0.43) | NAMPTALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-15 | — | — | US | claimed |
| EP-1898927-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2008-03-19 | — | — | EP | claimed |
| WO-2007002481-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | MERCK SHARP & DOHME CORP. | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179122-A1 | Non-Nucleoside Reverse Transcriptase Inhibitors | RNGTT, RTF1, POLR1E | NAMPT 58/4885ALDH1A1 1178/4885MAPT 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.